Wockhardt Limited — PPTs, 05-06-2025: Investor Presentation

1. Financial Highlights:

Wockhardt reported total income of INR 3,033 Cr, up 5% year-over-year, with EBITDA surging 67% to INR 418 Cr. EBITDA margin expanded to 14% from 9%, reflecting strong operational leverage. Net debt-to-equity ratio stands at a low 0.01, with debt reduced by INR 397 Cr to INR 64 Cr. Equity base increased to INR 4,657 Cr, and cash & cash equivalents are INR 615 Cr, indicating a healthy balance sheet and improved financial flexibility.

2. Strategic Initiatives & Growth Drivers:

Growth is driven by expanding diabetes biosimilars in India and emerging markets, focusing on insulin analogues and human insulin. Capacity for diabetes biosimilars is set to double over three years. Novel antibiotic ZAYNICH® (WCK 5222) completed global Phase III with superior efficacy; the NDA is filed in India, targeting a ~INR 17,000 Cr Indian market and a US$7 billion opportunity in the US and Europe. Miqnaf® (Nafithromycin), a new macrolide antibiotic, launched in India targeting the INR 10,800 Cr Indian respiratory infection market, with further global approvals underway.

3. Business Developments:

Wockhardt commercialized Miqnaf® and Emrok® series reaching over 100,000 patients. ZAYNICH® passed key development milestones, including Phase III global trials and regulatory filings in India and the US. The company raised INR 1,000 Cr via QIP to fund expansion plans. Manufacturing is shifting towards internal operations, accompanied by energy cost and waste reduction measures.

4. Market Position & Competitive Advantage:

Integrated R&D capabilities support Wockhardt’s leadership in antibiotics and diabetes biosimilars, with facilities in India and the UK. Their novel antibiotics address multi-drug resistant infections, a largely underserved global segment. Miqnaf® is the first new macrolide antibiotic in over 30 years, boasting better lung concentration and resistance coverage. The biosimilars pipeline benefits from patented drug delivery devices and gains from market shifts like Novo Nordisk scaling back human insulin pens.

5. Investor Implications:

Focus on novel antibiotics and diabetes biosimilars underpins positive growth potential, supported by strong margins and niche leadership. A robust balance sheet and recent capital raise enhance capacity expansion and R&D. Execution risks lie in regulatory approvals and commercialization scale-up, but an innovation-driven portfolio and large addressable markets present attractive opportunities for investors.